Chan Karissa, Fischer Corinne, Maralani Pejman Jabehdar, Black Sandra E, Moody Alan R, Khademi April
Department of Electrical, Computer and Biomedical Engineering, Toronto Metropolitan University, Toronto, ON Canada.
Institute for Biomedical Engineering, Science Tech (iBEST), a Partnership between St. Michael's Hospital and Toronto Metropolitan University, Toronto, ON Canada.
Npj Imaging. 2024;2(1):56. doi: 10.1038/s44303-024-00063-x. Epub 2024 Dec 31.
This study proposes a framework to stratify vascular disease patients based on brain health and cerebrovascular disease (CVD) risk using regional FLAIR biomarkers. Intensity and texture biomarkers were extracted from FLAIR volumes of 379 atherosclerosis patients. K-Means clustering identified five homogeneous subgroups. The 15 most important biomarkers for subgroup differentiation, identified via Random Forest classification, were used to generate biomarker profiles. ANOVA tests showed age and white matter lesion volume were significantly ( < 0.05) different across subgroups, while Fisher's tests revealed significant ( < 0.05) differences in the prevalence of several vascular risk factors across subgroup. Based on biomarker and clinical profiles, Subgroup 4 was characterized with neurodegeneration unrelated to CVD, Subgroup 3 identified patients with high CVD risk requiring aggressive intervention, and Subgroups 1, 2, and 5 identified patients with varying levels of moderate risk, suitable for long-term lifestyle interventions. This study supports personalized treatment and risk stratification based on FLAIR biomarkers.
本研究提出了一个框架,用于使用区域液体衰减反转恢复(FLAIR)生物标志物,根据大脑健康状况和脑血管疾病(CVD)风险对血管疾病患者进行分层。从379例动脉粥样硬化患者的FLAIR体积中提取强度和纹理生物标志物。K均值聚类确定了五个同质亚组。通过随机森林分类确定的用于亚组区分的15个最重要生物标志物,被用于生成生物标志物概况。方差分析测试显示,各亚组间年龄和白质病变体积存在显著差异(<0.05),而费舍尔检验显示,几个血管危险因素的患病率在亚组间存在显著差异(<0.05)。基于生物标志物和临床概况,第4亚组的特征是与CVD无关的神经退行性变,第3亚组确定为需要积极干预的高CVD风险患者,第1、2和5亚组确定为具有不同程度中度风险的患者,适合长期生活方式干预。本研究支持基于FLAIR生物标志物的个性化治疗和风险分层。